Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials
Signal Transduct Target Ther. 2017 Oct 9:2:17054.
doi: 10.1038/sigtrans.2017.54.
eCollection 2017.